$0.41
6.80% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US03828A1016
Symbol
APLT
Sector
Industry

Applied Therapeutics, Inc. Stock price

$0.44
-0.02 3.88% 1M
-7.95 94.74% 6M
-0.42 48.49% YTD
-5.93 93.08% 1Y
-2.05 82.29% 3Y
-30.61 98.58% 5Y
-8.96 95.31% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.02 4.15%
ISIN
US03828A1016
Symbol
APLT
Sector
Industry

Key metrics

Market capitalization $51.31m
Enterprise Value $-45.59m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 8.71
Cash position $98.87m
P/E forward negative
P/S forward 112.58
EV/Sales forward negative
Short interest 17.46%

Is Applied Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Applied Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Applied Therapeutics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Applied Therapeutics, Inc.:

Hold
100%

Financial data from Applied Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.12 0.12
-
100%
- Direct Costs 0.10 0.10
17% 17%
83%
0.02 0.02
117% 117%
17%
- Selling and Administrative Expenses 15 15
232% 232%
12,358%
- Research and Development Expense 15 15
37% 37%
12,358%
-30 -30
93% 93%
-24,700%
- Depreciation and Amortization 0.10 0.10
17% 17%
83%
EBIT (Operating Income) EBIT -30 -30
92% 92%
-24,783%
Net Profit -69 -69
62% 62%
-57,158%

In millions USD.

Don't miss a Thing! We will send you all news about Applied Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Applied Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commissi...
Neutral
GlobeNewsWire
15 days ago
Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions
Neutral
PRNewsWire
about 2 months ago
NEW YORK , Feb. 16, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline. So what: If you purchased Applied Therapeutics securities during the Cla...
More Applied Therapeutics, Inc. News

Company Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Head office United States
CEO Les Funtleyder
Founded 2016
Website www.appliedtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today